SG10201500957QA - Anti-nerve growth factor antibodies and methods of preparing and using the same - Google Patents
Anti-nerve growth factor antibodies and methods of preparing and using the sameInfo
- Publication number
- SG10201500957QA SG10201500957QA SG10201500957QA SG10201500957QA SG10201500957QA SG 10201500957Q A SG10201500957Q A SG 10201500957QA SG 10201500957Q A SG10201500957Q A SG 10201500957QA SG 10201500957Q A SG10201500957Q A SG 10201500957QA SG 10201500957Q A SG10201500957Q A SG 10201500957QA
- Authority
- SG
- Singapore
- Prior art keywords
- preparing
- methods
- same
- growth factor
- nerve growth
- Prior art date
Links
- 229940053128 nerve growth factor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/467—Igs with modifications in the FR-residues only
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161483491P | 2011-05-06 | 2011-05-06 | |
| US201161531439P | 2011-09-06 | 2011-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201500957QA true SG10201500957QA (en) | 2015-04-29 |
Family
ID=46168541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013081914A SG194795A1 (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| SG10201500957QA SG10201500957QA (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013081914A SG194795A1 (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20140170136A1 (en) |
| EP (2) | EP2705056B1 (en) |
| JP (2) | JP6181043B2 (en) |
| KR (1) | KR101833465B1 (en) |
| CN (1) | CN103764677A (en) |
| AU (1) | AU2012252153B2 (en) |
| BR (1) | BR112013028652A8 (en) |
| CA (1) | CA2834983C (en) |
| ES (1) | ES2704007T3 (en) |
| GB (1) | GB2504888B (en) |
| MY (1) | MY160884A (en) |
| RU (1) | RU2640252C2 (en) |
| SG (2) | SG194795A1 (en) |
| WO (1) | WO2012153123A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX359070B (en) | 2010-12-01 | 2018-09-13 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof. |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| MY160884A (en) * | 2011-05-06 | 2017-03-31 | Nexvet Australia Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| PT3083694T (en) | 2013-12-20 | 2024-02-01 | Intervet Int Bv | Caninized murine anti-canine pd-1 antibodies |
| BR112017006203A2 (en) | 2014-09-30 | 2018-05-02 | Intervet International B.V. | isolated, caninized and monoclonal antibodies or antigen binding fragment thereof, isolated nucleic acid, expression vector, host cell, isolated antigenic peptide, fusion protein, pharmaceutical composition, and method of enhancing the activity of an immune cell. |
| CN104774265B (en) * | 2015-02-12 | 2018-05-04 | 北京华安科创生物技术有限公司 | The neutralizing monoclonal antibody 11F1 and its hybridoma cell strain of anti human nerve growth factor |
| CN104910274B (en) * | 2015-02-12 | 2018-05-04 | 北京华安科创生物技术有限公司 | The neutralizing monoclonal antibody 12C11 and its hybridoma cell strain of anti human nerve growth factor |
| MA42138A (en) * | 2015-05-22 | 2018-03-28 | Astellas Pharma Inc | NEW Fab FRAGMENT OF ANTIBODIES AGAINST HUMAN NGF |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| BR112020002871A2 (en) * | 2017-08-15 | 2020-07-28 | Kindred Biosciences, Inc. | fc igg variants for veterinary use |
| GB2578867A (en) * | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
| AU2019250128A1 (en) | 2018-10-15 | 2020-04-30 | Avent Inc. | Compositions, systems, kits, and methods for neural ablation |
| MX2023013165A (en) | 2021-05-12 | 2023-11-30 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof. |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| AU632843B2 (en) * | 1989-08-10 | 1993-01-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| PT1696031E (en) | 1991-12-02 | 2010-06-25 | Medical Res Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| SE9400088D0 (en) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| DE19742706B4 (en) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | lipocalin muteins |
| WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| ITRM20030601A1 (en) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED. |
| NZ549990A (en) * | 2004-04-07 | 2009-08-28 | Rinat Neuroscience Copr | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| ITRM20050290A1 (en) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS. |
| CA2622441A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| WO2010027488A2 (en) * | 2008-09-04 | 2010-03-11 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| PE20121540A1 (en) | 2009-05-04 | 2012-12-22 | Abbott Res Bv | ANTIBODIES AGAINST NERVOUS GROWTH FACTOR (NGF) WITH IMPROVED IN VIVO STABILITY |
| JP2013520999A (en) * | 2010-03-04 | 2013-06-10 | ベット・セラピューティクス・インコーポレイテッド | Monoclonal antibody against CD52 |
| EP2542262A4 (en) * | 2010-03-04 | 2014-02-26 | Vet Therapeutics Inc | Monoclonal antibodies directed to cd20 |
| AU2011291462A1 (en) * | 2010-08-19 | 2013-03-14 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
| MY160884A (en) * | 2011-05-06 | 2017-03-31 | Nexvet Australia Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
-
2012
- 2012-05-08 MY MYPI2013702081A patent/MY160884A/en unknown
- 2012-05-08 KR KR1020137032545A patent/KR101833465B1/en active IP Right Grant
- 2012-05-08 RU RU2013154307A patent/RU2640252C2/en not_active Application Discontinuation
- 2012-05-08 BR BR112013028652A patent/BR112013028652A8/en not_active Application Discontinuation
- 2012-05-08 US US14/115,772 patent/US20140170136A1/en not_active Abandoned
- 2012-05-08 JP JP2014509819A patent/JP6181043B2/en active Active
- 2012-05-08 CA CA2834983A patent/CA2834983C/en active Active
- 2012-05-08 CN CN201280033623.8A patent/CN103764677A/en active Pending
- 2012-05-08 GB GB1320050.6A patent/GB2504888B/en active Active
- 2012-05-08 EP EP12723732.9A patent/EP2705056B1/en active Active
- 2012-05-08 AU AU2012252153A patent/AU2012252153B2/en active Active
- 2012-05-08 SG SG2013081914A patent/SG194795A1/en unknown
- 2012-05-08 WO PCT/GB2012/051004 patent/WO2012153123A1/en active Application Filing
- 2012-05-08 ES ES12723732T patent/ES2704007T3/en active Active
- 2012-05-08 EP EP18205439.5A patent/EP3502136A1/en not_active Withdrawn
- 2012-05-08 SG SG10201500957QA patent/SG10201500957QA/en unknown
-
2017
- 2017-04-05 JP JP2017075108A patent/JP6526089B2/en active Active
-
2018
- 2018-09-12 US US16/129,674 patent/US20190276525A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ617448A (en) | 2015-01-30 |
| AU2012252153A1 (en) | 2013-11-14 |
| BR112013028652A2 (en) | 2016-11-29 |
| AU2012252153A8 (en) | 2013-12-19 |
| KR20140041532A (en) | 2014-04-04 |
| JP6526089B2 (en) | 2019-06-05 |
| RU2640252C2 (en) | 2017-12-27 |
| JP2014519318A (en) | 2014-08-14 |
| CN103764677A (en) | 2014-04-30 |
| SG194795A1 (en) | 2013-12-30 |
| CA2834983A1 (en) | 2012-11-15 |
| EP3502136A1 (en) | 2019-06-26 |
| EP2705056A1 (en) | 2014-03-12 |
| ES2704007T3 (en) | 2019-03-13 |
| BR112013028652A8 (en) | 2017-12-26 |
| GB2504888B (en) | 2016-02-03 |
| GB2504888A (en) | 2014-02-12 |
| JP2017123870A (en) | 2017-07-20 |
| US20140170136A1 (en) | 2014-06-19 |
| JP6181043B2 (en) | 2017-08-16 |
| US20190276525A1 (en) | 2019-09-12 |
| MY160884A (en) | 2017-03-31 |
| RU2013154307A (en) | 2015-06-20 |
| CA2834983C (en) | 2020-11-17 |
| AU2012252153B2 (en) | 2016-07-07 |
| KR101833465B1 (en) | 2018-02-28 |
| GB201320050D0 (en) | 2013-12-25 |
| EP2705056B1 (en) | 2018-11-14 |
| WO2012153123A1 (en) | 2012-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2504887B (en) | Anti-Nerve growth factor antibodies and methods of preparing and using the same | |
| GB201517547D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| SG10201500960TA (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| GB2504888B (en) | Anti-Nerve growth factor antibodies and methods of preparing and using the same | |
| HK1255608A1 (en) | Anti-htra1 antibodies and methods of use | |
| HK1213581A1 (en) | Anti-cd40 antibodies and methods of use -cd40 | |
| HK1212256A1 (en) | Anti-mcam antibodies and associated methods of use -mcam | |
| ZA201308022B (en) | Anti-cd40 antibodies and methods of use | |
| EP2748199A4 (en) | Anti-ox40 antibodies and methods of using the same | |
| ZA201403760B (en) | Anti-cd98 antibodies and methods of use thereof | |
| HK1201843A1 (en) | Anti-polyubiquitin antibodies and methods of use | |
| GB201223276D0 (en) | Antibodies and methods of producing same | |
| ZA201306451B (en) | Anti-il-6 receptor antibodies and methods of use | |
| EP2771694A4 (en) | Monoclonal antibodies and methods of use | |
| EP2611832A4 (en) | Anti-cxcl13 antibodies and methods of using the same | |
| EP2663330A4 (en) | Anti-tlr4 antibodies and methods of use thereof | |
| EP2755667A4 (en) | Method for enhancing the growth and fullness of hair | |
| HK1199735A1 (en) | Caninised tumour necrosis factor antibodies and methods of using the same | |
| SG11201400405TA (en) | Caninised antibodies and method for the production of same | |
| HUS2200012I1 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| GB201519606D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| GB2505352B (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same |